最近发现的铜凋亡（一种新的铜离子诱导的细胞死亡途径）表明了治疗异质性和耐药性癌症的新治疗潜力。目前，基于铜离子载体的疗法已被设计用于治疗癌症，利用铜离子作为阻止肿瘤增殖和促进细胞死亡的战略工具。然而，基于铜离子载体的疗法的局限性包括铜离子的非靶向递送、肿瘤积累低和半衰期短。增强特异性的策略涉及使用基于纳米技术的药物靶向细胞内铜凋亡机制。此外，探索联合疗法的重要性怎么强调也不为过，因为它们是提高癌症治疗功效的关键策略。最近的研究报道了纳米药物的抗癌作用，可以在体外和体内诱导癌症的铜凋亡。这些针对铜凋亡的纳米药物可以利用铜离子的药代动力学特性提高递送效率，从而增强基于铜凋亡的抗癌作用。这篇综述将总结铜离子与癌症发生之间错综复杂的关系，探讨铜稳态及其失调在癌症进展和死亡中的关键作用。此外，我们还将介绍用于癌症治疗的铜凋亡靶向纳米药物的最新进展。最后，我们将讨论基于铜凋亡的纳米药物面临的挑战，以探讨未来的发展方向。版权所有 © 2024 Dahye Noh 等人。

The recent discovery of cuproptosis, a novel copper-ion-induced cell death pathway, has suggested the novel therapeutic potential for treating heterogeneous and drug-resistant cancers. Currently, copper ionophore-based therapeutics have been designed to treat cancers, utilizing copper ions as a strategic tool to impede tumor proliferation and promote cellular demise. However, limitations of copper ionophore-based therapies include nontargeted delivery of copper ions, low tumor accumulation, and short half-life. Strategies to enhance specificity involve targeting intracellular cuproptosis mechanisms using nanotechnology-based drugs. Additionally, the importance of exploring combination therapies cannot be overstated, as they are a key strategy in improving the efficacy of cancer treatments. Recent studies have reported the anticancer effects of nanomedicines that can induce cuproptosis of cancer both in vitro and in vivo. These cuproptosis-targeted nanomedicines could improve delivery efficiency with the pharmacokinetic properties of copper ion, resulting in increasing cuproptosis-based anticancer effects. This review will summarize the intricate nexus between copper ion and carcinogenesis, examining the pivotal roles of copper homeostasis and its dysregulation in cancer progression and fatality. Furthermore, we will introduce the latest advances in cuproptosis-targeted nanomedicines for cancer treatment. Finally, the challenges in cuproptosis-based nanomedicines will be discussed for future development directions.Copyright © 2024 Dahye Noh et al.